1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990; 322:1277–89.
2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388:2023–38.
Article
3. Talstad I, Scheie P, Dalen H, Röli J. Influence of plasma proteins on erythrocyte morphology and sedimentation. Scand J Haematol. 1983; 31:478–84.
Article
4. van Leeuwen MA, van Rijswijk MH, van der Heijde DM, Te Meerman GJ, van Riel PL, Houtman PM, et al. The acutephase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol. 1993; 32(Suppl 3):9–13.
Article
5. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum. 2000; 43:1473–7.
Article
6. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340:448–54.
Article
7. Yolbas S, Yildirim A, Gozel N, Uz B, Koca SS. Hematological indices may be useful in the diagnosis of systemic lupus erythematosus and in determining disease activity in behçet's disease. Med Princ Pract. 2016; 25:510–6.
Article
8. Mercan R, Bitik B, Tufan A, Bozbulut UB, Atas N, Ozturk MA, et al. The association between neutrophil/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal. 2016; 30:597–601.
Article
9. Liu JF, Ba L, Lv H, Lv D, Du JT, Jing XM, et al. Association between neutrophil-to-lymphocyte ratio and differentiated thyroid cancer: a meta-analysis. Sci Rep. 2016; 6:38551.
Article
10. Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med. 2012; 44:805–16.
Article
11. Okyay GU, Inal S, Oneç K, Er RE, Paş aoğlu O, Paş aoğlu H, et al. Neutrophil to lymphocyte ratio in evaluation of inflammation in patients with chronic kidney disease. Ren Fail. 2013; 35:29–36.
Article
12. Turkmen K, Erdur FM, Ozcicek F, Ozcicek A, Akbas EM, Ozbicer A, et al. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int. 2013; 17:391–6.
Article
13. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996; 7:157–61.
14. Tekeoğlu İ, Gürol G, Harman H, Karakeçe E, Çiftçi İ H. Overlooked hematological markers of disease activity in rheumatoid arthritis. Int J Rheum Dis. 2016; 19:1078–82.
Article
15. Zengin O, Onder ME, Kalem A, Bilici M, Türkbeyler IH, Ozturk ZA, et al. New inflammatory markers in early rheumatoid arthritis. Z Rheumatol. 2018; 77:144–50.
Article
16. Uslu AU, Küçük A, Şahin A, Ugan Y, Yılmaz R, Güngör T, et al. Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis. 2015; 18:731–5.
Article
17. Fu H, Qin B, Hu Z, Ma N, Yang M, Wei T, et al. Neutrophil- and platelet-to-lymphocyte ratios are correlated with disease activity in rheumatoid arthritis. Clin Lab. 2015; 61:269–73.
Article
18. Tecer D, Sezgin M, Kanık A, İncel NA, Çimen ÖB, Biçer A, et al. Can mean platelet volume and red blood cell distribution width show disease activity in rheumatoid arthritis? Biomark Med. 2016; 10:967–74.
Article
19. Talukdar M, Barui G, Adhikari A, Karmakar R, Ghosh UC, Das TK. A study on association between common haematological parameters and disease activity in rheumatoid arthritis. J Clin Diagn Res. 2017; 11:EC01–4.
20. Yazici S, Yazici M, Erer B, Erer B, Calik Y, Ozhan H, et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets. 2010; 21:122–5.
Article
21. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008; 75:291–4.
Article
22. Gasparyan AY, Stavropoulos-Kalinoglou A, Toms TE, Douglas KM, Kitas GD. Association of mean platelet volume with hypertension in rheumatoid arthritis. Inflamm Allergy Drug Targets. 2010; 9:45–50.
Article
23. Maden M, Pamuk GE, Pamuk ÖN. Development of atherosclerotic cardiovascular mortality in gouty arthritis and rheumatoid arthritis patients: are they associated with mean platelet volume and neutrophil-lymphocyte ratio? A comparative study. Arch Rheumatol. 2017; 32:39–45.
Article
24. Zhang YY, Yin YM, Kuai SG, Shan ZB, Pei H, Wang J. Combination of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as diagnostic biomarker for rheumatoid arthritis. Int J Clin Exp Med. 2016; 9:22076–81.
25. Gökmen F, Akbal A, Reşorlu H, Binnetoglu E, Cevizci S, Gökmen E, et al. Mean platelet volume and neutrophil lymphocyte ratio as related to inflammation markers and an-ti-CCP in rheumatoid arthritis. Aktuel Rheumatol. 2016; 41:488–91.
Article
26. Cakır L, Aktas G, Mercimek OB, Enginyurt O, Kaya Y, Mercimek K. Are red cell distribution width and mean platelet volume associated with rheumatoid arthritis? Biomed Res. 2016; 27:292–4.
27. Yildirim A, Karabiber M, Surucu GD, Türkbeyler IH, Karakoyun A, Selkuc MY, et al. The changes of mean platelet volume and platelet distribution width in patients with rheumatoid arthritis and their correlation with disease activity. Arch Sicil Med Chir 4 Acta Med Mediterr. 2015; 31:1105–11.
28. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010; 19:703–10.
Article
29. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus. 2009; 18:9–15.
Article
30. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis. Mol Biol Rep. 2010; 37:227–34.
Article
31. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097.
Article
32. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5:13.
Article
33. Ridout KK, Ridout SJ, Price LH, Sen S, Tyrka AR. Depression and telomere length: A meta-analysis. J Affect Disord. 2016; 191:237–47.
Article
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177–88.
Article
35. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539–58.
Article
36. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629–34.
Article
37. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol. 2013; 66:151–7.
Article
38. Rodríguez-Carrio J, Alperi-López M, López P, Alonso-Castro S, Carro-Esteban SR, Ballina-García FJ, et al. Red cell distribution width is associated with endothelial progenitor cell depletion and vascular-related mediators in rheumatoid arthritis. Atherosclerosis. 2015; 240:131–6.
Article
39. Milovanovic M, Nilsson E, Järemo P. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clin Chim Acta. 2004; 343:237–40.
Article
40. Chandrashekara S, Rajendran A, Bai Jaganath A, Krishnamurthy R. Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis. Reumatismo. 2015; 67:109–15.
Article
41. Harish R, Poorana PP. Changes in platelet indices in patients with Rheumatoid arthritis. Int J Pharma Bio Sci. 2015; 6:515–8.
42. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001; 344:907–16.
Article
43. Li J, Kim K, Barazia A, Tseng A, Cho J. Platelet-neutrophil interactions under thromboinflammatory conditions. Cell Mol Life Sci. 2015; 72:2627–43.
Article
44. Wood KL, Twigg HL 3rd, Doseff AI. Dysregulation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation. Front Biosci (Landmark Ed). 2009; 14:3771–81.
Article
45. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today. 1995; 16:21–6.
Article
46. Qin B, Ma N, Tang Q, Wei T, Yang M, Fu H, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol. 2016; 26:372–6.
Article
47. Koca TT. Does obesity cause chronic inflammation? The association between complete blood parameters with body mass index and fasting glucose. Pak J Med Sci. 2017; 33:65–9.
Article
48. Meng X, Wei G, Chang Q, Peng R, Shi G, Zheng P, et al. The platelet-to-lymphocyte ratio, superior to the neutrophil-to-lymphocyte ratio, correlates with hepatitis C virus infection. Int J Infect Dis. 2016; 45:72–7.
Article
49. Turhan O, Coban E, Inan D, Yalcin AN. Increased mean platelet volume in chronic hepatitis B patients with inactive disease. Med Sci Monit. 2010; 16:CR202–5.